ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.81−0.14 (-3.54%)
Close on Nov 12, 2026Market cap $378.89MP/E –Yield –
ARS Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
ARS Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$195.60M. For fiscal 2025 it was -$178.08M. The highest annual figure on record is -$3.00M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$178.08M | – |
| FY2024 | Dec 31, 2024 | -$3.00M | – |
| FY2023 | Dec 31, 2023 | -$67.42M | – |
| FY2022 | Dec 31, 2022 | -$35.42M | – |
| FY2021 | Dec 31, 2021 | -$19.24M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$33.76M | – |
| Q2 FY2026 | Jun 30, 2026 | -$61.05M | – |
| Q1 FY2026 | Mar 31, 2026 | -$59.75M | – |
| Q4 FY2025 | Dec 31, 2025 | -$41.05M | -186.9% |
| Q3 FY2025 | Sep 30, 2025 | -$52.80M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.34M | – |
| Q1 FY2025 | Mar 31, 2025 | -$36.90M | – |
| Q4 FY2024 | Dec 31, 2024 | $47.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.18M | – |
| Q4 FY2023 | Dec 31, 2023 | -$10.23M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.88M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.89M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.70M | – |
See a number that looks wrong?